Julie Appleby reports on the implementation of the health care overhaul law, the interplay of health care treatments and costs, trends in health insurance, and policy issues affecting hospitals and other medical providers. Her KHN stories have appeared in USA Today, the Washington Post, the Philadelphia Inquirer and MSNBC, among others. Before joining KHN in March 2009, Appleby spent 10 years on the health care industry and policy beat for USA Today. She also worked at the San Francisco Chronicle
, the Financial Times
in London and the Contra Costa Times
in Walnut Creek, Calif. She serves on the board of the Association of Health Care Journalists and her education includes a Master of Public Health degree. | Contact: JulieA@kff.org | @Julie_Appleby
Beginning in October, some states will score health plans on cancer screening rates and flu shot delivery, among other measures, to help consumers make smarter buying decisions.
The kiosks are part of a technology boom targeted at consumers seeking instant health data and cheaper, more convenient care.
Insurers bet some consumers will choose cheaper plans that restrict their choice of doctors, despite worries about skimpy care and huge bills for out-of-network providers.
The new online marketplaces, to be set up by October, are designed to make it easier to buy insurance. But they're in the middle of a political fight over the health care law.
What's at stake if they build state-based exchanges, partner with the federal government -- or let federal regulators run everything?
Insurers develop new business strategies as the health law upends old models.
The proposed regulations deal with several key issues, such as how plans structure their health benefits, the variations on premiums based on age and requirements for wellness programs.
Cascading delays related to technical issues could make October 2013 target for open enrollment difficult, if not impossible, to meet.
The Kaiser Permanente chairman and CEO offers his take on a wide variety of health care issues insurers face in the current marketplace.
Meningitis outbreak puts spotlight on rules favoring cheaper, but potentially riskier versions of drug to help prevent premature births.